Intercept Pharmaceuticals, Inc.
ICPTN/A
NASDAQBiotechnology🇺🇸North America
Drugs in Pipeline
7
Phase 3 Programs
2
Upcoming Catalysts
2
Next Catalyst
Sep 6, 2026
25wMarket Overview
Stock performance and key metrics
ICPT News
Catalyst Timeline
2 upcoming, 0 past
Drug Pipeline
Obeticholic Acid (OCA)
Primary Biliary Cirrhosis
Obeticholic acid (10 mg)
Compensated Cirrhosis
INT-747
Diabetes Mellitus, Type II
Obeticholic Acid
Primary Biliary Cirrhosis
Bezafibrate 100 mg
Primary Biliary Cholangitis
INT-787
Alcohol Associated Hepatitis
Atorvastatin
Nonalcoholic Steatohepatitis
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Obeticholic Acid (OCA) | Phase 3 | Primary Biliary Cirrhosis | - | - |
Obeticholic acid (10 mg) | Phase 3 | Compensated Cirrhosis | - | - |
INT-747 | Phase 2 | Diabetes Mellitus, Type II | - | - |
Obeticholic Acid | Phase 2 | Primary Biliary Cirrhosis | - | - |
Bezafibrate 100 mg | Phase 2 | Primary Biliary Cholangitis | - | - |
INT-787 | Phase 2 | Alcohol Associated Hepatitis | - | - |
Atorvastatin | Phase 2 | Nonalcoholic Steatohepatitis | - | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply